Tenet Healthcare Corp

Find Ratings Reports
THC : NYSE : Health Care
$31.60 | %
Today's Range: 0.00 - 0.00
Avg. Daily Volume: 1,415,500
07/26/16 - 4:01 PM ET

Financial Analysis


TENET HEALTHCARE CORP's gross profit margin for the first quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. TENET HEALTHCARE CORP has weak liquidity. Currently, the Quick Ratio is 0.83 which shows a lack of ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.

At the same time, stockholders' equity ("net worth") has significantly decreased by 25.50% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)5044.04424.0
EBITDA ($mil)589.0525.0
EBIT ($mil)377.0318.0
Net Income ($mil)-59.047.0


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)728.0185.0
Total Assets ($mil)23766.018425.0
Total Debt ($mil)14522.012334.0
Equity ($mil)625.0839.0


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin11.6811.87
EBITDA Margin11.6711.86
Operating Margin7.477.19
Sales Turnover0.810.93
Return on Assets-1.030.49
Return on Equity-38.8812.75
Debt Q1 FY16 Q1 FY15
Current Ratio1.21.37
Debt/Capital0.960.94
Interest Expense243.0199.0
Interest Coverage1.551.6


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)99.2799.16
Div / share0.00.0
EPS-0.560.46
Book value / share6.38.46
Institutional Own % n/a n/a
Avg Daily Volume1441144.02380961.0

Valuation


HOLD. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 4.95 indicates a significant premium versus the S&P 500 average of 2.81 and a significant premium versus the industry average of 3.34. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. After reviewing these and other key valuation criteria, TENET HEALTHCARE CORP proves to trade at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
THC NM Peers 21.90   THC 2.50 Peers 12.23

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

THC's P/E is negative making this valuation measure meaningless.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

THC is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
THC 12.62 Peers 16.46   THC NA Peers 0.95

Average. An average price-to-projected earnings ratio can signify an industry neutral stock price and average future growth expectations.

THC is trading at a valuation on par with its peers.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
THC 4.95 Peers 3.34   THC -331.13 Peers 22.01

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

THC is trading at a significant premium to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, THC is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
THC 0.16 Peers 0.81   THC 12.58 Peers 14.30

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

THC is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

THC trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades